Telix Pharmaceuticals
(OTC) TLPPF
Telix Pharmaceuticals Financials at a Glance
Market Cap
$3.22B
Revenue (TTM)
A$2.01B
Net Income (TTM)
A$39.06M
EPS (TTM)
-$0.02
P/E Ratio
-450.24
Dividend
$0.00
Beta (Volatility)
0.44 (Low)
Dividend
$0.00
Beta (Volatility)
0.44 (Low)
Price
$9.50
Volume
54
Open
$9.50
Price
$9.50
Volume
54
Open
$9.50
Previous Close
$9.50
Daily Range
$9.50 - $9.50
52-Week Range
$5.91 - $17.00
Estimated Earnings Date
Aug 20, 2026
Dividend
$0.00
Beta (Volatility)
0.44 (Low)
Price
$9.50
Volume
54
Open
$9.50
Previous Close
$9.50
Daily Range
$9.50 - $9.50
52-Week Range
$5.91 - $17.00
Estimated Earnings Date
Aug 20, 2026
TLPPF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Telix Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
234
CEO
Christian P. Behrenbruch, PhD, EMBA
Website
www.telixpharma.comHeadquarters
North Melbourne, VIC 3051, AU
TLPPF Financials
Key Financial Metrics (TTM)
Gross Margin
51%
Operating Margin
2%
Net Income Margin
-1%
Return on Equity
-2%
Return on Capital
2%
Return on Assets
-1%
Earnings Yield
-0.22%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$3.22B
Shares Outstanding
339.38M
Volume
54
Avg. Volume
2.38K
Financials (TTM)
Gross Profit
A$661.81M
Operating Income
A$27.54M
EBITDA
A$82.52M
Operating Cash Flow
-A$26.81M
Capital Expenditure
-A$58.78M
Free Cash Flow
-A$85.59M
Cash & ST Invst.
A$212.66M
Total Debt
A$784.94M
Telix Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
A$630.70M
+123.9%
Gross Profit
A$332.84M
+48.6%
Gross Margin
52.77%
N/A
Market Cap
$3.22B
N/A
Market Cap/Employee
$7.77M
N/A
Employees
415
N/A
Net Income
-A$7.37M
-137.7%
EBITDA
A$29.40M
+27.9%
Quarterly Fundamentals
Net Cash
-A$572.28M
-640.9%
Accounts Receivable
A$207.42M
+220.2%
Inventory
A$55.58M
+221.1%
Long Term Debt
A$756.97M
+4665.0%
Short Term Debt
A$27.97M
+1694.0%
Return on Assets
-0.61%
N/A
Return on Invested Capital
1.81%
N/A
Free Cash Flow
-A$94.47M
-3426.4%
Operating Cash Flow
-A$54.35M
-611.5%